Upstream Bio to Participate in the Piper Sandler 36th Annual Healthcare Conference
Upstream Bio to Participate in the Piper Sandler 36th Annual Healthcare Conference
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin, a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plans to initiate development in chronic obstructive pulmonary disease. Upstream Bio's team is committed to maximizing verekitug's unique attributes to address the substantial unmet needs for patients underserved by today's standard of care. To learn more, please visit .WALTHAM, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, MPH, Upstream Bio's CEO, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024 at 2:00 p.m. ET.
美国马萨诸塞州沃尔瑟姆，2024年11月21日（环球新闻通讯社）-- Upstream Bio, Inc.（纳斯达克：UPB）是一家临床阶段公司，专注于开发治疗炎症疾病的疗法，最初侧重于严重呼吸疾病。今天宣布，Upstream Bio首席执行官Rand Sutherland博士将于2024年12月3日下午2:00参与派杰投资第36届年度医疗会议的炉边聊天。
A live webcast of the presentation will be available under the "Events" tab on the "Investors" page on the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
活动当天，公司的演示将通过网络直播的方式在公司网站的“投资者”页面的“事件”标签下提供。网络直播的回放将在演示后存档于公司网站上90天。
About Upstream Bio
关于Upstream Bio
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin, a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plans to initiate development in chronic obstructive pulmonary disease. Upstream Bio's team is committed to maximizing verekitug's unique attributes to address the substantial unmet needs for patients underserved by today's standard of care. To learn more, please visit .
Upstream Bio是一家临床阶段的生物技术公司，专注于开发治疗炎症疾病的疗法，最初侧重于严重呼吸疾病。该公司正在开发verekitug，这是目前在临床开发中唯一已知的针对胸腺基质淋巴细胞刺激因子受体的拮抗剂，这是一种经过临床验证的炎症反应驱动因子，处于多个信号通路的上游，影响多种免疫介导的疾病。该公司已将这一高效单克隆抗体推进到治疗严重哮喘和慢性鼻窦炎伴鼻息肉的两个独立的第二阶段临床试验，并计划在慢性阻塞性肺疾病中启动开发。Upstream Bio的团队致力于最大化verekitug的独特属性，以满足当今治疗标准无法满足的患者的重大需求。要了解更多信息，请访问。
CONTACT: Investor Contact:
Michael Gray
Chief Financial Officer and Chief Operating Officer
ir@upstreambio.com
Media Contact:
Teri Dahlman
Red House Communications
teri@redhousecomms.com
投资者联系方式:
迈克尔·格雷
首席财务官和首席运营官
ir@upstreambio.com
媒体联系：
特里•达尔曼
Red House Communications
teri@redhousecomms.com
